Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunic, Inc. filings document SEC reporting for a Nasdaq-listed biotechnology company developing oral therapies for neurologic disease. Recent Form 8-K reports cover financial results and corporate updates, Nasdaq minimum bid price compliance, stockholder-approved charter amendments, and the reverse stock split affecting its common stock.
Governance disclosures include director and officer appointments, executive compensation arrangements, special-meeting voting results, and definitive proxy materials. The filings also describe registered common stock, capital-structure changes, financing and clinical-program updates, and formal governance and shareholder voting subjects tied to Immunic's late-stage development model.
Immunic, Inc. received an updated ownership disclosure from Nantahala Capital Management and its principals, Wilmot B. Harkey and Daniel Mack. As of December 31, 2025, they may be deemed to beneficially own 10,378,406 shares of Immunic common stock, representing 8.22% of the outstanding shares.
This stake includes 6,000,000 shares that can be acquired within sixty days through the exercise of warrants. The reporting persons have shared, but no sole, voting and dispositive power over these shares. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Immunic.
Immunic, Inc. plans an oversubscribed private placement providing upfront gross proceeds of USD 200 million, with additional potential proceeds of up to USD 200 million through warrant exercises, for total financing of up to USD 400 million. The company will issue 229,076,000 pre-funded warrants at $0.873 each and matching warrants to purchase up to 229,076,000 common shares at an exercise price of $0.873 per share, expiring the earlier of 30 days after topline Phase 3 ENSURE data or February 17, 2031.
Immunic expects this capital, together with existing cash, to fund operations to late 2027, including completion of Phase 3 ENSURE trials in relapsing multiple sclerosis, initiation of a Phase 3 trial in primary progressive multiple sclerosis, and preparation for commercialization of vidofludimus calcium. Separately, the company agreed to cancel 51,087,000 previously issued Series B warrants in exchange for a right to an aggregate 5% royalty on future vidofludimus calcium net sales, leaving 35,579,667 Series B warrants outstanding.
The company will seek stockholder approval for a reverse stock split at a ratio of at least 10:1. Governance changes include appointing BVF principal Thor Nagel to the board, elevating Simona Skerjanec to interim Chairperson, and the resignation of director Maria Törnsén, which was not due to any disagreement with the company.
Immunic, Inc. received an amended Schedule 13G/A from Aberdeen Group plc and its subsidiary abrdn Inc. reporting a significant ownership position in the company’s common stock.
The filing shows beneficial ownership of 8,243,941 Immunic common shares, representing 6.85% of the class as of 12/31/2025. Both Aberdeen Group plc and abrdn Inc. report shared power to vote and dispose of these shares, with no sole voting or dispositive power.
The securities are stated to be acquired and held in the ordinary course of business, and not for the purpose of changing or influencing control of Immunic. Aberdeen Group plc is identified as the parent company, with abrdn Holdings Limited as intermediate holding company for abrdn Inc.
Immunic, Inc. is moving its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the opening of business on January 7, 2026, while continuing to trade under the symbol IMUX.
The company previously fell out of compliance with Nasdaq’s $1.00 minimum bid price rule and did not regain compliance by the initial December 24, 2025 deadline, triggering this transfer request. With Nasdaq’s approval, Immunic now has an additional 180 days, until June 22, 2026, for its common stock to maintain a minimum $1.00 bid price for at least 10 consecutive business days to regain compliance. As a condition of this extension, Immunic has notified Nasdaq that it will seek to implement a reverse stock split, if needed, and faces potential delisting if compliance is not achieved and any subsequent appeal is unsuccessful.
Immunic, Inc. furnished a current report to note that it has issued a press release announcing its financial results for the quarter ended September 30, 2025 and providing a corporate update. The press release is included as Exhibit 99.1 to the report, but the company specifies that this information is being furnished, not filed, so it is not subject to certain liability provisions of the securities laws or automatically incorporated into other SEC filings.
Immunic, Inc. filed its Q3 2025 report, highlighting continued losses and liquidity pressure. The company reported a net loss of $25,579 for the quarter and $77,872 for the nine months ended September 30, 2025. Cash and cash equivalents were $35,132, while net cash used in operating activities reached $66,525 for the nine-month period.
Current liabilities were $30,079 against total stockholders’ equity of $10,499, down from $18,429 at year-end. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital. During 2025, Immunic raised $60,661 from a May offering and $4,734 from an April offering to fund operations. The company also received a Nasdaq notice for failure to maintain the $1.00 minimum bid, with a compliance window through December 24, 2025. Immunic continues advancing late-stage oral therapies, including vidofludimus calcium in Phase 3 for relapsing multiple sclerosis.
Immunic, Inc. announced presentations of vidofludimus calcium data at the 41st ECTRIMS congress in Barcelona, held September 24-26, 2025. The company issued a press release dated September 25, 2025, and posted a corporate presentation on its website on September 24, 2025, which includes new data from the Phase 2 CALLIPER trial in progressive multiple sclerosis. The filing lists the press release and the presentation as exhibits and states the report was signed by CEO Daniel Vitt.
Immunic, Inc. is registering 7,000,000 additional shares of common stock for issuance under its 2019 Omnibus Equity Incentive Plan, as amended. On April 20, 2025, the board approved an amendment to the plan, subject to stockholder approval, to raise the total shares authorized for issuance under the plan to 26,448,871. Stockholders approved this amendment on June 4, 2025, and this Form S-8 filing implements that approval.
The newly registered shares are of the same class as those covered by prior Form S-8 registrations and will be issuable to eligible participants in the 2019 plan. Immunic also restates its standard Delaware-law based indemnification and director-and-officer insurance protections for its directors and officers in connection with securities law liabilities.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh report beneficial ownership equal to 9.9% of Immunic, Inc. common stock on a fully‑diluted, exercise‑limited basis. The filing discloses that the reporting persons hold warrants to purchase 11,250,000 shares but, due to exercise limitations in the warrant terms, may only exercise for up to 9,485,936 shares, representing 9.9% of the issuer based on 95,817,536 outstanding shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Nantahala Capital Management, LLC and two individuals report a 9.99% beneficial interest in Immunic, Inc. The filing shows Nantahala, together with Wilmot B. Harkey and Daniel Mack, may be deemed the beneficial owners of 10,634,565 shares of Immunic common stock, representing 9.99% of the class as of June 30, 2025. The amount reported includes shares that may be acquired within 60 days through exercise of warrants. The Reporting Persons disclose shared voting and dispositive power over these shares and identify BLACKWELL PARTNERS LLC - SERIES A as a fund with the right to receive dividends or sale proceeds for more than 5% of the shares reported. The filing certifies the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control.